Shao Yingjie, Geng Yiting, Gu Wendong, Huang Jin, Ning Zhonghua, Pei Honglei
Department of Radiation Oncology, The Third Affiliated Hospital of Soochow University, 185 Juqian Street, Changzhou, Jiangsu Province 213003, China.
Department of Oncology, The Third Affiliated Hospital of Soochow University, 185 Juqian Street, Changzhou 213003, China.
Dis Markers. 2014;2014:626185. doi: 10.1155/2014/626185. Epub 2014 Oct 23.
Recently, many studies have shown that microRNAs (miRNA) exhibit altered expression in various cancers and may play an important role as prognostic biomarker of cancers. We performed a meta-analysis to evaluate the impact of miR-375 expression in solid tumors on patients' overall survival (OS).
Studies were identified by searching PubMed, Embace, and Cochrane Library (last search update was in May 2014) and were assessed by further quality evaluation. The pooled hazard ratios (HRs) with 95% confidence intervals (CIs) for total and stratified analyses were calculated to investigate the association between miR-375 expression and cancer patients OS.
Our analysis results indicated that downregulation of miR-375 predicted poor OS (HR = 1.91, 95% CI 1.48-2.45, P < 0.001). Subgroup analyses showed that lower expression of miR-375 was significantly related with poor OS in patients with esophageal carcinoma (HR = 2.24, 95% CI 1.69-2.96, P < 0.001) and non-small-cell lung cancer (NSCLC) (HR = 1.71, 95% CI 1.31-2.24, P < 0.001).
The findings from this meta-analysis suggest that miR-375 expression is associated with OS of patients with malignant tumors and could be a useful clinical prognostic biomarker.
最近，许多研究表明，微小RNA（miRNA）在各种癌症中表达发生改变，可能作为癌症的预后生物标志物发挥重要作用。我们进行了一项荟萃分析，以评估miR-375在实体瘤中的表达对患者总生存期（OS）的影响。
通过检索PubMed、Embace和Cochrane图书馆（最后一次检索更新于2014年5月）来识别研究，并通过进一步的质量评估进行评估。计算总分析和分层分析的合并风险比（HRs）及其95%置信区间（CIs），以研究miR-375表达与癌症患者OS之间的关联。
我们的分析结果表明，miR-375的下调预示着较差的OS（HR = 1.91，95% CI 1.48 - 2.45，P < 0.001）。亚组分析显示，miR-375表达较低与食管癌患者（HR = 2.24，95% CI 1.69 - 2.96，P < 0.001）和非小细胞肺癌（NSCLC）患者（HR = 1.71，95% CI 1.31 - 2.24，P < 0.001）的较差OS显著相关。
这项荟萃分析的结果表明，miR-375表达与恶性肿瘤患者的OS相关，可能是一种有用的临床预后生物标志物。
